Table 1.
BPRS and CGI scores and anandamide blood levels of the twelve patients with schizophrenia included in this study.
| Patient Number | Anandamide levels in the blood during the acute phase of schizophrenic illness (pmol/ml) | Anandamide levels in the blood during remission of schizophrenic illness (pmol/ml) | BPRS (and CGI) Scores Acute Remission |
| 1 | 11.7 | 59 (5) | |
| 2 | 7.3 | 64 (5) | |
| 3 | 8.4 | 4.4 | 68 (6) 25 (1) |
| 4 | 8.2 | 48 (4) | |
| 5 | 6.3 | 6.2 | 60 (5) 20 (1) |
| 6 | 5.3 | 2.2 | 66 (6) 29 (2) |
| 7 | 7.7 | 4.1 | 56 (5) 26 (1) |
| 8 | 6.7 | 2.5 | 70 (6) 29 (2) |
| 9 | 7.5 | 55 (4) | |
| 10 | 9.7 | 57 (4) | |
| 11 | 8.7 | 56 (4) | |
| 12 | 6.0 | 52 (5) | |
|
7.79 ± 0.50 (P = 4.5 × 10-8 vs. Control) |
3.88 ± 0.72 (P = 0.16 vs. Control) |
||
Five of these patients were assessed before and after remission of the symptoms (indicated by the significant decrease in the global BPRS and CGI scores) induced by treatment with olanzapine. CGI score ranged from 6 (severely affected) to 1 (much improved), and are shown in parentheses. The amount of anandamide in healthy volunteers (control) was 2.58 ± 0.28 pmol/ml (mean ± SEM, n = 20). Means were compared to the control by the unpaired Student's t test, threshold of significance was 0.95.